Back

Durable survival benefits of acoramidis over 54 months in variant transthyretin amyloid cardiomyopathy (ATTR-CM), including p.V142I: interim findings from ATTRibute-CM and its open-label extension

30 August 2026 (10:45 - 10:57)
Organised by: Logo
Congress Presentation Part of: New directions in cardiac amyloidosis Infiltrative Myocardial Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Assistant Professor Kevin Alexander

Stanford University School of Medicine, Palo Alto (United States of America)

4 More presentations in this session

Presentation thumbnail
Low aortic valve calcium score as an imaging red flag for concomitant transthyretin cardiac amyloidosis in severe aortic stenosis: A CAUSATIVE study subanalysis
Doctor A. Cantone (Ferrara, IT)
Abstract Slides Video
Presentation thumbnail
Cardiac amyloidosis exhibits a distinct PAR2-linked transcriptional program
Ms E. Ghanbari (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Predictors of recurrent ischemic stroke in cardiac amyloidosis
Mr C. Ng (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Prognostic significance of low alanine aminotransferase in patients with transthyretin amyloid cardiomyopathy
Doctor C. Choy (Birmingham, GB)
Abstract Slides Video

Access the full session

Session thumbnail
New directions in cardiac amyloidosis
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 10:45 CET
You may be interested in
thumbnail
Congress Presentation
Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension
30 August 2024
thumbnail
Congress Presentation
Survival analysis in a population with cardiac amyloidosis
22 May 2023
thumbnail
Congress Presentation
Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study
30 August 2025
thumbnail
Congress Presentation
Long-term integrated safety of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources